| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2876523df340f4a499e22ffcb5b3dfcb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6839 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate |
2018-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fea5d7fe568fbf96bc62641bd222cfd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_092a1cee45ae6b049c8a89d13bd73933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c258397e4ec19efbdfadb59c61d349b |
| publicationDate |
2019-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-I658848-B |
| titleOfInvention |
Zika virus vaccine composition and application thereof |
| abstract |
The present invention provides a Zika virus envelope protein mutant and a nucleic acid molecule comprising a nucleotide sequence encoding the mutant. The Zika virus envelope protein mutant is preferably a threonine substitution at the 105th amino acid position of a wild-type Zika virus envelope protein, or at the 248th and 250th amino acid positions, respectively. One day the asparagine and monothreonine were substituted, so it had an N-glycan that masked the fusion loop region of the Zika virus envelope protein. The invention also provides a vaccine composition comprising the Zika virus envelope protein mutant or a recombinant virus having the nucleic acid molecule. The invention also provides the use of the Zika virus envelope protein mutant, which is used to prepare a vaccine composition for preventing Zika virus infection and reducing the antibody-dependent enhancement effect of dengue virus infection. |
| priorityDate |
2018-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |